Sitagliptin and weight loss
Pro Research Analysisby 
Searched over 200M research papers
Sitagliptin and Weight Loss in Type 2 Diabetes and Obesity
Modest Weight Loss with Sitagliptin Monotherapy and Combination Therapy
Research shows that sitagliptin, whether used alone or in combination with metformin, can lead to modest weight loss in overweight and obese patients with type 2 diabetes. A large meta-analysis found that sitagliptin alone resulted in an average weight loss of about 1 kg, and when combined with metformin, the weight loss was slightly greater, around 1.1 kg, over a period of more than six months. Both body weight and body mass index (BMI) were reduced compared to placebo, indicating a consistent, though modest, effect on weight reduction 13.
Comparative Effectiveness: Sitagliptin vs. Other Diabetes Medications
When compared to sulfonylureas, another class of diabetes medications, sitagliptin is associated with weight loss, while sulfonylureas often cause weight gain. Studies show that patients on sitagliptin lost about 2 kg more than those on sulfonylureas, though this difference is considered modest and may not be clinically significant for all individuals 57. In both older and younger adults, sitagliptin led to lower body weight after 12 months compared to sulfonylureas, with weight reductions of about 1.4 kg in older adults and 2.3 kg in younger adults .
Impact of Baseline BMI on Weight Change
The effect of sitagliptin on weight may depend on a person’s starting BMI. In one study, obese patients experienced greater weight loss after three months of sitagliptin treatment compared to those with normal or overweight BMI. Interestingly, people with normal BMI saw a slight increase in weight, while overweight individuals had no significant change .
Sitagliptin in Combination with Metformin and Other Agents
Adding sitagliptin to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) resulted in significant reductions in body weight, intrahepatic lipid, and visceral fat over 26 weeks. The weight loss observed with sitagliptin was similar to that seen with liraglutide, another diabetes medication known for its weight loss effects, and both were superior to insulin glargine, which did not affect weight .
Mechanisms: Inflammation, Oxidative Stress, and Fat Metabolism
Animal studies suggest that sitagliptin may help reduce obesity by decreasing inflammation and oxidative stress in fat tissue. In obese mice, sitagliptin reversed weight gain, reduced fat accumulation, and improved markers of inflammation and oxidative stress . In humans, sitagliptin improved glucose tolerance and lipid metabolism but did not significantly change body weight or energy expenditure in overweight men with prediabetes over 12 weeks .
Long-Term and Real-World Outcomes
Long-term studies indicate that sitagliptin maintains its modest weight loss effect over time. However, switching from sitagliptin to oral semaglutide, a newer diabetes medication, resulted in greater weight loss, suggesting that while sitagliptin is effective, other agents may offer more substantial weight reduction for some patients .
Conclusion
Sitagliptin is associated with modest weight loss or weight neutrality in overweight and obese patients with type 2 diabetes, especially when used for more than six months or combined with metformin. Its weight loss effect is greater than that of sulfonylureas and may be more pronounced in individuals with higher baseline BMI. While the weight loss is generally small, sitagliptin remains a favorable option for patients concerned about weight gain with diabetes treatment.
Sources and full results
Most relevant research papers on this topic